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Experimental autoimmune myasthenia gravis (EAM) is an autoimmune
disease of the neuromuscular junction, recently induced in animals by injection
of purified acetylcholine receptor (AChR) extracted from electric fish, in
complete Freund's adjuvant (CFA). Rabbits (1-3) and monkeys (4) usually
display acute muscle weaknesses and die of severe difficulties in breathing.
Guinea pigs and rats (5) usually develop a mild disease, often transient,
manifested clinically by hypoactivity, sinking of head, and weight loss. The
experimental muscle disease may temporarily be reversed by the administration
of anticholinesterase agents, and a decremental response of muscle activity to
repetitive nerve stimulation can be demonstrated in electromyographic examina-
tion . Thus, EAM serves as an experimental model for the human autoimmune
disease myasthenia gravis (MG) in which the same clinical, pharmacological,
and electrophysiological phenomena are observed as a result of neuromuscular
junction block probably due to autoimmunization toward the postsynaptic
AChR.
In this report we demonstrate the passive transfer of EAM in strain 13 guinea
pigs . This was achieved by transfer of lymph node cells from guinea pigs
immunized with purified AChR from Torpedo californica to recipient animals.
Materials and Methods
Acetylcholine Receptor Antigen.
￿
Purified AChR from the electrogenic tissue of T. californica was
obtained by solubilization of membrane fragments with 1% Triton X-100, followed by affinity
chromatography on a Naja naja siamensis neurotoxin-Sepharose resin, as described by Aharonov et
al. (6), with slight modifications, for isolation of AChR from the electric eel . Thespecific activity of
the purified AChR was 8,000-10,000 pmol toxin bound per mg of protein.
Animals. Histocompatible strain 13 female guinea pigs weighing 300-400 g were used in all
experiments.
Transfer Procedure.
￿
Donor animals were injected into foot pads with 100 Ag ofthepurified AChR
in CFA (Difco Laboratories, Detroit, Mich.) . 8-10 days after challenge, donor animals were
anaesthized and exsanguinated by cardiac puncture . Lymph nodes were removed and placed in
minimal essential medium for suspension (Microbiological Associates, Jerusalem), finely minced,
and filtered through nylon mesh. The cell suspension was centrifuged for 5 min at 200 g in the cold
and the packed cells were resuspended in the above medium and washed twice. Portions were
removed for cell counting and viability was determined by trypan blue exclusion. Approximately2 x
10° cells with 70-80% viability were obtained from each donor. 5 x 10° viable cells were then injected
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into each recipient [2.5 x 10' intravenously (i.v .) and 2 .5 x 10' intraperitoneally (i.p .) ] ; this repre-
sents a donor :recipient ratio of 4:1 .
Skin Test .
￿
Intradermal injection of 15 ugAChR in 0.15 ml of the AChR purification buffer (0.01
M Tris-Cl, pH 7 .5 containing 0.1 M NaCl, 1 mM EDTA and 0.1% Triton X-100) were given to
actively challenged animals 10 days after immunization, to cell recipients 5 days after cell transfer,
and to normal control animals . The appearance of erythema at the site of injection was observed 24 h
later, and the extent of delayed hypersensitivity was quantitated by measuring the diameter of the
skin reaction . Skin reactions with a diameter larger than 5 mm were considered positive .
Humoral Response. Quantitative microcomplement fixation reactions were carried out, as
described by Levine (7) in donor animals 8-10 days after challenge .
Pharmacological and Neurophysiological Studies . The anticholinesterase, tensilon (edro-
phonium hydrochloride, 0 .1 mg), was injected i.v . to sick animals . Electromyographic examinations
(EMG) were performed on actively challenged animals 12-18 days after challenge and in recipients
8-12 days after cell transfer, using an HP Electromyograph . The stimulating electrodes were inserted
subcutaneously at the buttock, above the sciatic nerve, about 0 .5 cm apart. A tetanic train of
rectangular pulses, of 150 V amplitude and 100 /Asec duration, at a frequency of 40 Hz, was
administered for about 20 sec . The EMG was recorded by coaxial electrode which was inserted deep
into the calf muscle .
Results
Passive transfer ofEAM was accomplished, in three experiments, with lymph
node cells obtained from 56 donors sensitized with AChR and 14 recipient guinea
pigs . In a typical experiment, clinical signs ofEAM were observed in 6 out of 10
actively challenged animals 12-22 days after injection of AChR . Such signs were
observed in 8 out of 14 recipients 7-14 days after cell transfer . The disease was
FIG 1 .
￿
Evoked compound motor action potentials (ECMAP) in calf muscle of a recipient
guinea pig with EAM (A) and of a normal guinea pig (B) . The calibration in the upper traces is
in both cases : horizontal, 2 sec/div ; vertical, 2.5 mV/div . In the lower traces the calibration is :
horizontal, 5 msec/div ; vertical, 2 .5 mV/div . The lower traces show single ECMAP evoked on
early, intermediate and late stages of the repetitive stimulation shown in the upper traces .TARRAB-HAZDAI ET AL.
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characterized by mild generalized muscle weakness, sinking of the head,
hypoactivity, anorexia, and weight loss. This syndrome was transient, usually
lasting 3-4 days. Muscle weakness could be reversed for about 15 min
immediately after i.v. administration of tensilon. Neurophysiological examina-
tions revealed a decrease in amplitude during repetitive nerve stimulation in all
AChR-injected animals, as well as in all recipients (Fig. 1 A). A normal response
was observed in nonimmunized animals, and in animals injected with CFA alone
(Fig. 1 B). All actively challenged animals and also all recipients exhibited
delayed hypersensitivity as demonstrated by a positive skin test (above 5 mm
diameter) with 15 gg of AChR. The average diameters ofthe skin reactions were
19.6 mm for actively challenged animals and 9.2 mm for the recipients. No
response was revealed with a nonrelated control antigen (lysozyme) . No
circulating antibodies to AChR were detected by the microcomplement fixation
assay in the sera of donor animals, when sacrificed 8-10 days after challenge.
Discussion
In the present study we have reported the passive transfer ofEAM in strain 13
guinea pigs. The clinical picture of muscle weakness in about60% ofthe animals
as well as thecharacteristic improvementafter anticholinesterase agent adminis-
tration and the pathognomonic electromyographic decremental muscle response
torepetitive nervestimulation, were similarto thesame phenomenon observed in
parallel in actively challenged animals, and indicates that therecipients suffered
from EAM. This experimental AChR-induced disease has the same neurological,
pharmacological and electrophysiological manifestations as the human autoim-
mune disease MG, in which a specific cellular sensitization towards AChR
(8-10), as well as antibodies in some cases', has been recently demonstrated by
us. The induction ofEAM in experimental animals by injecting AChR, and the
immune response towards AChRin patients suffering from MG, provideevidence
for the breakdown oftolerance to self-AChR as the cause ofthe disease. Both the
immunopharmacological neuromuscular blockage and the thymic disorders
which are characteristic of the disease may involve the AChR as autoantigen
(11).
The results of the present study, as well as the demonstration ofa prominent
lymphocyte response to AChR in MG patients (9, 10), suggest that cellular
immunity plays a significant role in the pathogenesis ofmyasthenia gravis. Such
findings have also been reported for other autoimmune conditions which have
been related to delayed hypersensitivity . For example, cellular immunity
towards the myelin basic protein has been observed in acute postinfections
disseminated encephalomyelitis (12), and passive transfer has been demon-
strated in its experimental model, experimental allergic encephalomyelitis (13).
The mechanism by which suspensions of sensitized lymphocytes induce EAM
in recipient animals is not clearly defined. Sensitized cells may act either directly
on the neuromuscular junction, or indirectly, by releasing antibodies or nonim-
`Aharonov, A., O. Abramsky, R. Tarrab-Hazdai, and S. Fuchs. 1975. Humoral antibodies to
acetylcholine receptor in patients with myasthenis gravis. Lancet. In press.788
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munoglobulin mediators. No conclusive information as to the role of cells vs.
antibodies in the production of the motorend plate abnormality can be provided
from the present study. The relative contribution ofthe cellular response andthe
humoral antibodies in both EAM induced in animals and in the human disease,
MG, await further investigation.
Summary
Passive transfer of experimental autoimmune myasthenia (EAM) was per-
formed with lymph node cells from donor guinea pigs immunized with purified
acetylcholine receptor (AChR) from Torpedo californica. Recipient animals
revealed the same clinical signs and electromyographic patterns as observed in
actively challenged animals. These phenomena are parallel to the clinical
manifestations of the human disease myasthenia gravis, in which cellular
response to AChR was recently demonstrated .
The authors wish to thank Dr. Israel Silman for fruitful discussions, and Mrs. Dora Barchan for
excellent technical assistance.
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